Lupin share price jumps nearly 7% on GBP 12.3 million acquisition of Renascience in UK

The stock rose as much as 6.98% to ₹2,150 per share on the National Stock Exchange (NSE). At 11:12 am, it was up 4.46% to ₹2,099.35 apiece.

In an exchange filing, the company said that Lupin Healthcare (UK) Ltd, with this acquisition, gains full ownership of Renascience, which will become its subsidiary.

"100% of the shareholding of Renascience Pharma Limited (RPL) has been acquired by Lupin Healthcare (UK) Limited, UK, wholly owned subsidiary of the company, thereby making RPL as its wholly owned subsidiary," the regulatory filing said.

The acquisition is not a related party transaction and none of the promoter or promoter group has any interest in the acquisition, it added.

Renascience's portfolio consists of two injectables for infectious diseases, oral therapy for indications in cardiology and nephrology, and ear drops for pain management. It recorded a turnover of GBP 3.51 million in the financial year 2024-25 (FY25), GBP 1.87 million in FY24, and GBP 0.72 million in FY23.

Fabrice Egros, President (Corporate Development) of Lupin, said, “In recent years Lupin has established a highly successful branded business in the UK delivering significant value to patients and the NHS (National Health Service). This strategic move allows Lupin to further enhance our branded medicine portfolio, catering to unmet medical needs and furthering our mission to provide accessible and sustainable healthcare solution."

Lupin's consolidated profit after tax (PAT) advanced 38.81% to ₹858.86 crore in the December quarter of the financial year 2024-25, compared to ₹618.8 crore in the same period a year ago.

Revenue from operations increased 10.97% to ₹5,767.71 crore in Q3 FY25 as against ₹5,197.41 crore a year back.